EMD LEXIGEN

House mark for pharmaceutical and biopharmaceutical products for the treatment of cancer, MDS, genetic disorders and immunological disorders; novel protein drugs for use in the area of oncology, immune therapies and for the treatment of metabolic disorders

House mark for scientific research and development in the area of pharmacy, medicine, biology and genetics, developing treatments for serious and life-threatening diseases as well as broad technology platforms that will lead to new therapies